![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Resverlogix Receives Health Canada Approval for Fabry Disease Clinical Trial with Apabetalone
Resverlogix Receives Health Canada Approval for Fabry Disease Clinical Trial with Apabetalone
June 2, 2017
Health Canada has granted approval to Resverlogix to proceed with a clinical trial of apabetalone in Fabry disease.
The disease is caused by a mutation in the GLA gene leading to a deficiency in the alpha galactosidase-A enzyme that breaks down a fatty substance called Gb3. This leads to abnormal deposits of Gb3 in blood vessel walls and tissues throughout the body that can damage major organs and shorten lifespan.
Apabetalone (RVX-208) is a selective BET (bromodomain and extra-terminal) inhibitor that can regulate disease-causing genes.
Upcoming Events
-
21Oct